TNFRSF17 and AL amyloidosis: BCMA, a member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17) and a transmembrane glycoprotein, stands as the key surface antigen target for CAR-T cell therapy for the treatment of multiple myeloma.